Why the study?
Does intracoronary Ac-RGDS-NH2 prevent platelet-dependent thrombus formation in a dog model compared to Ac-RGES-NH2?
Does intracoronary Ac-RGDS-NH2 prevent platelet-dependent thrombus formation in a dog model compared to Ac-RGES-NH2?
Answers are grounded in this paper and cite their sources.
Ac-RGDS-NH2 is an effective and specific antiplatelet agent that inhibits thrombus formation when administered intracoronary in a dog model.
This study compared the anti-platelet effect of Ac-RGDS-NH2 which is a peptide fragment from fibrinogen to Ac-RGES-NH2 in which the aspartic acid (D) of Ac-RGDS-NH2 has been replaced by glutamic acid (E). When Ac-RGDS-NH2 was infused intracoronary at concentrations of 100-400 mM, acute platelet-dependent thrombus formation in the dog coronary artery was inhibited. However, infusion of Ac-RGES-NH2 intracoronary at similar concentrations to Ac-RGDS-NH2 failed to inhibit platelet-dependent thrombus formation in the dog. Ac-RGDS-NH2 and Ac-RGES-NH2 were also tested for their ability to inhibit collagen-induced platelet aggregation in vitro. Ac-RGDS-NH2 elicited concentration-dependent inhibition of collagen-induced aggregation with no effect of Ac-RGES-NH2 on collagen-induced platelet aggregation. Thus, Ac-RGDS-NH2 is an effective antiplatelet agent after intracoronary administration in the dog and also inhibits collagen-induced platelet aggregation in vitro. Ac-RGDS-NH2 is a specific inhibitor of platelet aggregation as replacement of the aspartic acid in Ac-RGDS-NH2 with glutamic acid results in complete loss of biological activity.
No takes yet. Share an insight, caveat, or question.
Shebuski et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: